project id: TCGA-UCEC; case submitter id: TCGA-AX-A3G3; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.4; rna integrity number: 7.6; age at index: 58; days to birth: -21308; ethnicity: not reported; gender: female; race: white; vital status: Alive; year of birth: 1951; age at diagnosis: 21308; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 42.0; figo stage: Stage IIIA; icd 10 code: C54.1; last known disease status: not reported; morphology: 8441/3; primary diagnosis: Serous cystadenocarcinoma, NOS; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: Not Reported; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2009; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 713; initial weight: 140.0; oct embedded: false; preservation method: Unknown; sample id: 5efdace8-5790-4239-8e8a-6349f88b10dd; sample submitter id: TCGA-AX-A3G3-01A; portion id: 347e1242-0979-4b60-84c9-e4f2a333fe7e; portion submitter id: TCGA-AX-A3G3-01A-11; slide id: 279081b2-ed01-4949-bdef-2a72abca5131; slide submitter id: TCGA-AX-A3G3-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 15.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 3.0; percent tumor cells: 82.0; percent tumor nuclei: 97.0; section location: TOP;